Home/Pipeline/CLK/DYRK Dual Inhibitor (Compound 9)

CLK/DYRK Dual Inhibitor (Compound 9)

Osteoarthritis

Preclinical (IND candidate)Active

Key Facts

Indication

Osteoarthritis

Phase

Preclinical (IND candidate)

Status

Active

Company

Curadev

About Curadev

Curadev is a private, clinical-stage biotechnology company founded in 2015, advancing a pipeline of novel small molecule drugs. Its lead asset, CRD3874-SI, is a first-in-class allosteric STING agonist in Phase 1 trials via a collaboration with Memorial Sloan Kettering Cancer Center. The company also has preclinical programs targeting STING antagonism, TNIK, and CLK/DYRK, supported by a leadership team with deep, long-standing relationships in drug discovery.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Metabolic Disorders Neuroinflammation Osteoarthritis

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
Osteoarthritis Program	OrthoSera	Pre-clinical	Active
CYT-108	Cytonics	Phase 2	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
4P004	4P-Pharma	Phase II	Active